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2 Enteric-formulated capsules can mitigate gastrointestinal (GI) side-
3 effects following sodium bicarbonate (NaHCO3) ingestion however, it 
4 remains unclear how encapsulation alters post-ingestion symptoms 
5 and acid-base balance. The current study aims to identify the optimal 
6 ingestion form to mitigate GI distress following NaHCO3 ingestion. 
7 Fourteen trained males ingested 300 mg∙kg-1 body mass (BM) 
8 NaHCO3 in gelatine (GEL), delayed-release (DEL) and enteric-coated 
9 (ENT) capsules or placebo (PLA) in a randomised crossover design. 
10 Blood bicarbonate anion concentration [HCO3–], potential hydrogen 
11 (pH) and GI symptoms were measured pre- and post-ingestion for 3 h. 
12 Fewer GI symptoms were reported with ENT NaHCO3 than with GEL 
13 (P = 0.012) but not DEL (P = 0.106) in the post-ingestion phase. 
14 Symptom severity decreased with DEL (4.6 ± 2.8 AU) compared to 
15 GEL (7.0 ± 2.6 AU; P = 0.001) and were lower with ENT (2.8 ± 1.9 
16 AU) than with both GEL (P < 0.0005) and DEL (P = 0.044) NaHCO3. 
17 Blood [HCO3–] increased in all NaHCO3 conditions compared to PLA 
18 (P < 0.0005), although this was lower with ENT than GEL (P = 0.001) 
19 and DEL (P < 0.0005) NaHCO3. Changes in peak blood pH were 
20 reduced with ENT than with GEL (P = 0.047) and DEL (P = 0.047) 
21 NaHCO3 with no other differences between conditions. Ingestion of 
22 ENT NaHCO3 attenuates GI disturbances up to 3h post-ingestion. 
23 Therefore, ENT ingestion forms may be favourable for those who 
24 report GI disturbances with NaHCO3 supplementation, or for those 
25 who have previously been deterred from its use altogether.
26
27 Key words: buffering agent, acid-base balance, delayed-release
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29 Gastrointestinal (GI) disturbances are widely reported following 
30 sodium bicarbonate (NaHCO3) supplementation (Burke & Pyne, 2007; 
31 Cameron et al., 2010; Kahle et al., 2013) and although the aetiology of 
32 GI disturbances involves multiple mechanisms, the neutralisation of 
33 gastric acid is considered a prominent factor (Turnberg, 1970). Rapid 
34 increases in gastric carbon dioxide tension occur from an effervescent 
35 reaction between gastric acid and NaHCO3, which can induce bloating, 
36 abdominal pain and vomiting (Carr et al., 2011a). Given the adverse 
37 side-effects experienced by some athletes, NaHCO3 ingestion may not 
38 be practical during competition despite its potential performance-
39 enhancing effects, which may deter athletes from supplementation 
40 (Heibel et al., 2018). Furthermore, previous findings suggest that GI 
41 symptoms can negate the performance-enhancing effects of NaHCO3 
42 (Carr et al., 2011b), and in some cases, may even be ergolytic 
43 (Cameron et al., 2010; Froio de Araujo Dias et al., 2015; Saunders et 
44 al., 2014). Irrespective of performance, little is known about the acute 
45 and chronic consequences of regular GI disturbances, which may be 
46 detrimental to health. Previous investigations have examined the 
47 efficacy of various ingestion strategies such as multiday dosing 
48 (Mueller et al., 2013), split-dosing (Sale et al., 2011) and carbohydrate 
49 co-ingestion (Carr et al., 2011a) to reduce GI disturbances. However, 
50 regardless of adopting these strategies, GI disturbances remain 
51 problematic in some individuals following ingestion, therefore 
52 emphasising the need for alternative ingestion strategies (Lancha 
53 Junior et al., 2015).
54 Enteric-formulated capsules can reduce side-effects 
55 associated with the ingestion of acid-sensitive compounds such as 
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56 NaHCO3 (Barbosa et al., 2017). Through encapsulation in a polymer 
57 barrier, which is less soluble at high acidity (Mazarati et al., 2016), 
58 capsules resist disintegration in the stomach and compounds are 
59 released in the small intestine, therefore preventing GI disturbances. 
60 Recent evidence suggests that delayed-release NaHCO3, which 
61 contained an enteric-coating within the shell, minimises GI symptoms 
62 in comparison to an oral solution while inducing comparable acid-base 
63 balance (Hilton et al., 2019). There is however speculation as to how 
64 the site of disintegration may alter the bioavailability of bicarbonate, 
65 which is thought to be a factor modulating its ergogenic effects (Heibel 
66 et al., 2018). Whilst minimising the loss of bicarbonate anions in the 
67 stomach may augment blood concentrations (Oliveira et al., 2018), 
68 delaying absorption also decreases GI transit time; which in turn may 
69 reduce changes in blood bica bonate. These considerations suggest 
70 that bioavailability may be complex; one factor relates to GI transit 
71 time while another to the degree of neutralisation. Therefore, overall 
72 bioavailability is dependent upon on the balance between bicarbonate 
73 losses through neutralisation and GI transit time which is determined 
74 by the ingestion form. While previous research has compared the 
75 effects of administering NaHCO3 in gelatine (Carr et al., 2011a) and 
76 delayed-release capsules in comparison to an oral solution (Hilton et 
77 al., 2019), research has yet to compare the effects of different capsule 
78 ingestion forms. Consequently, little is currently known regarding how 
79 enteric coatings may affect GI symptoms and bicarbonate kinetics 
80 following NaHCO3 supplementation. Furthermore, there is a notable 
81 lack of data regarding the efficacy of commercially available capsule 
82 formulations, despite this being a potential form of ingestion for 
83 athletes.
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84 The primary aim of the present study was to determine the 
85 optimal ingestion form to minimise GI disturbances following 
86 NaHCO3 ingestion. The secondary aim was to examine the 
87 bioavailability of bicarbonate anions following NaHCO3 ingestion 




92 Fourteen trained (according to DePauw et al., 2013) males (age 23.6 ± 
93 4.9 years, BM 80.9 ± 11.5 kg, maximal oxygen uptake 57.7 ± 5.3 
94 mL∙kg-1∙min-1) volunteered for the study. All participants performed 
95 regular exercise training (≥ 3 d∙week-1) for at least two years and were 
96 free of GI-related disorders. Exclusion criteria included those with 
97 hypertension, renal impairment or following a salt-restricted diet, and 
98 no participants were ingesting buffering agents or medications at the 
99 time of the study. Protocols were explained in full and questions were 
100 answered before the participants gave written, informed consent to 
101 participate in the study. Ethical approval was granted by the 
102 institutional research ethics committee.
103
104 Experimental overview
105 In a double-blind, placebo-controlled, randomised crossover design, 
106 participants attended the laboratory on five separate occasions. After 
107 an initial visit, experimental trials consisted of a placebo (PLA) and 
108 three NaHCO3 trials, whereby 300 mg∙kg-1 BM NaHCO3 was 
109 administered in either gelatine (GEL), delayed-release (DEL) or 
110 enteric-coated (ENT) capsules. According to the manufacturer, the 
111 DEL capsules (DRcaps™) were embedded with a polymer barrier 
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112 (Hypromellose) within the shell, whereas the ENT capsules 
113 (Bicarbi™) were spray-coated with the same ingredient. Experimental 
114 trials were counterbalanced (balanced Latin-square) in the order of 
115 administration and conducted at least 48 h apart to allow for blood 
116 bicarbonate concentration ([HCO3–]) to return to ‘normal’ values. 
117 Participants were required to abstain from alcohol or caffeine-
118 containing beverages for 12 h, and strenuous exercise 24 h before each 
119 laboratory visit.
120 During the initial visit, semi-nude BM was measured (BOD 
121 POD®, COSMED, Italy) before participants performed an incremental 
122 exercise test to volitional exhaustion on an electromagnetically-braked 
123 cycle ergometer (Excalibur Sport, Lode, Netherlands). This involved 
124 a standardised warm-up (5 min at 70 W) before the workload increased 
125 by 1 W every 2 s (30 W·min-1) until volitional exhaustion was reached.
126 Experimental trials took place under standardised laboratory 
127 conditions (temperature 20-22 °C, humidity 50 ± 5 %) and commenced 
128 at the same time of day to account for circadian rhythms (Reilly et al., 
129 1990). Participants arrived at the laboratory after an overnight fast (~ 
130 12 h) which was verbally confirmed upon arrival. Participants then 
131 ingested 300 mg·kg-1 BM NaHCO3 or PLA (cornflour) which were 
132 administered in size 0 opaque (white) capsules. Each experimental 
133 capsule contained 650 mg NaHCO3 therefore doses were administered 
134 to the nearest whole capsule. Capsules were manually filled by the 
135 same individual using a capsule filling device (Capsule Connection 
136 LLC, USA) and doses were tested for accuracy (Fisher, OHAUS™). 
137 Supplements were ingested with an equal volume (6 mL·kg-1 BM) of 
138 water (Evian®, France) within 5 min while the timing commenced at 
139 the start of ingestion (Stannard et al., 2016). Given that water was 
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140 permitted ad libitum post-ingestion, volumes were recorded on the first 
141 trial and replicated thereafter. Participants remained seated throughout 
142 although toilet breaks were permitted.
143
144 Assessment of acid-base balance
145 During each trial, the exposure-response was established by 
146 determining the time course of blood [HCO3–] and potential hydrogen 
147 (pH). Fingertip capillary blood samples (95 μL) were obtained pre-
148 ingestion and then every 20 min for 180 min post-ingestion, with 10 
149 min sampling from 80 to 140 min. Samples were collected in heparin-
150 coated glass capillary tubes (Radiometer Medical Ltd, Denmark) using 
151 an aseptic technique and were analysed immediately (Radiometer 
152 ABL800 BASIC, Denmark) for blood [HCO3–] and pH. Blood 
153 bicarbonate kinetics were used to determine characteristics of the 
154 ingestion forms, including lag time (Tlag), peak blood [HCO3–] (Cmax), 
155 change in Cmax (∆Cmax), time-to-reach Cmax (Tmax) and area under the 
156 curve (AUC). Bicarbonate Tlag was defined as the point at which blood 
157 [HCO3–] increased beyond normal daily fluctuation; established 
158 individually following ingestion of PLA.
159
160 Gastrointestinal symptoms
161 Symptoms of GI distress were recorded at the same time points using 
162 a 9-item questionnaire (adapted from Carr et al., 2011a) including 
163 nausea, flatulence, stomach cramping, belching, stomach ache, bowel 
164 urgency, diarrhoea, vomiting, and stomach bloating. Symptoms were 
165 self-measured on a 10 cm visual analogue scale ranging from “0, no 
166 symptom” to “10, severe symptom” (Miller et al., 2016).  Symptom 
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167 terminology was explained to participants before the experimental 
168 trials commenced to ensure consistency in the reporting of symptoms.
169
170 Statistical analysis
171 Data were assessed for normality using standard graphical methods 
172 prior to analyses (Grafen & Hails, 2002). Blood [HCO3–], pH and 
173 aggregated GI symptom scores were analysed using two-way (trial × 
174 time) analysis of variance (ANOVA) with repeated-measures. Where 
175 a significant main effect was found, Bonferroni post-hoc pair-wise 
176 comparisons were determined (Atkinson, 2002). One-way ANOVA 
177 with repeated measures were used to compare peak GI symptom 
178 scores, Tlag, Cmax, ∆ Cmax, Tmax and AUC between trials. Effect sizes 
179 were calculated using partial eta squared (ηp2) and were described as 
180 trivial (<0.20 AU), small (0.20-0.49 AU), moderate (0.50-0.79 AU) or 
181 large ( 0.80 AU) as previously suggested (Cohen, 1988). The α-level 
182 of statistical significance was set at P < 0.05 and values for P of 
183 “0.000” given by the statistical package were corrected to “< 0.0005” 
184 (Kinnear & Gray, 1995). Relationships between peak GI symptom 
185 scores were determined using Pearson’s correlation coefficients. 
186 Descriptive data are presented as mean ± standard deviation (SD) 
187 unless stated otherwise. Data were analysed using the Statistical 




192 Ingestion form had a significant effect on GI symptoms (F1.4, 17.7 = 10.3, 
193 P = 0.003, ηp2 = 0.44) with lower GI symptom scores observed during 
194 PLA compared to the GEL (P = 0.011), DEL (P = 0.005) and ENT (P 
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195 = 0.02) trials (Figure 1). The ENT trial also resulted in significantly 
196 lower GI symptom scores compared to GEL (4.8 ± 1.4 AU; 95% CI 
197 1.0-8.6 AU; P = 0.025) but not DEL (P = 0.211) post-ingestion. Time 
198 had no effect on GI symptoms (F1.8, 23.8 = 2.1, P = 0.148, ηp2 = 0.14) 
199 and there was no significant trial × time interaction (F2.6, 34.0 = 1.8, P = 
200 0.180, ηp2 = 0.12).
201
202 [INSERT FIGURE 1 NEAR HERE]
203
204 The highest individual GI symptom (Table 2) occurred at ~ 60 
205 to 90 min (GEL 94 ± 58 min, DEL 91 ± 21 min, ENT 73 ± 34 min) 
206 and was significantly earlier with ENT than in the GEL (P = 0.028) 
207 trial. No other differences were observed in the time to reach peak GI 
208 symptom scores (P > 0.05) between trials. In total, eleven participants 
209 experienced GI symptoms at the point of Tmax in the GEL trial 
210 compared with seven and one in the DEL and ENT trials respectively, 
211 although these were rated as less than 3/10 AU throughout. Significant 
212 relationships were observed between peak GI symptoms in the DEL 
213 trial with all other NaHCO3 trials (GEL r = 0.78, P = 0.001; ENT r = 
214 0.64, P = 0.014). No other relationships were observed in peak GI 
215 symptoms between trials.
216 All fourteen participants experienced at least one GI symptom 
217 in the GEL trial, compared to twelve participants in the DEL and ENT 
218 trials (Table 2). Only two participants reported any GI symptoms in 
219 the PLA trial. Stomach bloating (100.0%), belching (92.9%) and 
220 bowel urgency (92.9%) were the most common GI symptoms overall, 
221 whereas diarrhoea (7.8 ± 3.1 AU), bowel urgency (5.9 ± 3.0 AU) and 
Page 8 of 27
Human Kinetics, 1607 N Market St, Champaign, IL 61825
International Journal of Sport Nutrition and Exercise Metabolism
For Peer Review
9




226 Ingestion form had a significant effect on blood [HCO3–] (F3.0, 39.0 = 
227 53.6, P < 0.0005, ηp2 = 0.81) and pH (F3.0, 39.0 = 50.7, P < 0.0005, ηp2 = 
228 0.80) (Figure 2). Blood [HCO3–] and pH were significantly lower with 
229 ENT than with GEL and DEL in the post-ingestion phase. In the post-
230 ingestion time period, there were significant effects on blood [HCO3–] 
231 (F3.4, 44.1 = 143.8, P < 0.0005, ηp2 = 0.92) and pH (F5.3, 68.5 = 36.3, P < 
232 0.0005, ηp2 = 0.74). Blood [HCO3–] at 110 min was significantly higher 
233 than at baseline, 20 and 40 min (P < 0.0005). Blood pH was 
234 significantly higher at 140 min than at baseline and 20 min (P < 
235 0.0005). Significant trial × time interactions were observed for blood 
236 [HCO3–] (F5.2, 67.3 = 28.9, P < 0.0005, ηp2 = 0.69) and pH (F8.3, 108.3 = 
237 6.0, P < 0.0005, ηp2 = 0.32) (Figure 2 for significant differences 
238 between trials at each time point). No changes in blood [HCO3–] or pH 
239 were observed for PLA throughout the post-ingestion phase (P > 0.05).
240
241 [INSERT FIGURE 2 NEAR HERE]
242
243 After NaHCO3 ingestion, ∆Cmax was lower in the ENT trial 
244 than in the GEL (P = 0.001) and DEL (P < 0.0005) trials (Figure 3) 
245 however, the values were similar during the GEL and DEL trials (6.5 
246 ± 1.2 mmol·L-1 and 6.0 ± 1.3 mmol·L-1, respectively; P = 0.116). 
247 During the GEL trial Tmax occurred within 60 to 90 min post-ingestion 
248 for most participants (n = 9) although this was not the case for DEL (n 
249 = 2) and ENT (n = 3). Blood pH peaked at similar time points across 
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250 trials (GEL 101 ± 30 min, DEL 119 ± 23 min, ENT 113 ± 32 min; P > 
251 0.05), with no significant differences between trials. Changes in peak 
252 blood pH were similar in the GEL (0.08 ± 0.02 AU) and DEL (0.08 ± 
253 0.02 AU) trials, whereas changes with ENT (0.06 ± 0.02) were 
254 significantly lower than with GEL (P = 0.047) and DEL (P = 0.047) 
255 NaHCO3.
256
257 [INSERT FIGURE 3 NEAR HERE]
258
259 DISCUSSION
260 The present study is the first to investigate the effects of capsule 
261 ingestion form on GI disturbances and acid-base balance following 
262 NaHCO3 ingestion. The key finding is that enteric-coated NaHCO3 
263 results in fewer and less seve e GI symptoms compared to both the 
264 gelatine and delayed-release capsules. Furthermore, enteric-coated 
265 NaHCO3 resulted in very few participants experiencing GI symptoms 
266 at the point of peak blood [HCO3–]; a time when exercise is likely to 
267 be scheduled for athletes using individualised ingestion strategies 
268 (Heibel et al., 2018). Interestingly, blood [HCO3–] was increased above 
269 5 mmol∙L-1 for longer with delayed-release NaHCO3 compared to the 
270 gelatine capsules (Figure 2), which may provide a greater ‘ergogenic 
271 window’ following supplementation (Carr et al., 2011b), although this 
272 has yet to be confirmed. Altogether, these data suggest that enteric-
273 coated capsules are more effective at attenuating GI symptoms 
274 following NaHCO3 ingestion however, delayed-release NaHCO3 
275 maximises extracellular buffering capacity. 
276 In the present study GI symptoms were reported by 85.7% of 
277 the participants across all NaHCO3 ingestion trials, which is higher 
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278 than some studies have previously reported (Driller et al., 2012; Sale 
279 et al., 2011; Saunders et al., 2014). Stomach bloating, belching and 
280 bowel urgency were the most common reported GI symptoms overall 
281 and although less frequent, the severity of diarrhoea was particularly 
282 high (Table 1). As expected, GI symptoms decreased following 
283 delayed-release and enteric-coated NaHCO3 ingestion compared to the 
284 gelatine capsules, therefore suggesting that bypassing the stomach can 
285 alleviate many of the symptoms associated with acute bicarbonate 
286 loading (Oliveira et al., 2018). In relation to causes of GI symptoms, 
287 these are unlikely to be due to the large number of capsules ingested 
288 since only minor symptoms were experienced with the placebo. 
289 Instead, GI symptoms can be attributed to the NaHCO3 alone, which 
290 also highlights that in some athletes, symptoms are likely to occur with 
291 oral delivery despite substantially fewer side-effects with enteric-
292 formulated capsules. Given the relationships observed for GI 
293 symptoms between ingestion forms, it appears that some individuals 
294 are more prone to GI disturbances than others, although the reasons for 
295 this are currently unclear.
296 Exercise timed with peak alkalosis may optimise performance 
297 benefits (Gough et al., 2018), therefore it is prudent to consider which 
298 GI symptoms will occur at this timepoint. While all participants 
299 reported at least one GI symptom post-ingestion, only three 
300 participants reported GI symptoms at the point when exercise would 
301 likely commence. Of these participants, all were experiencing severe 
302 diarrhoea (10.0 AU) at the point of peak alkalosis, which may 
303 negatively affect subsequent exercise performance (Deb et al., 2018; 
304 Saunders et al., 2014). Nevertheless, it is difficult to suggest which GI 
305 symptoms may adversely affect exercise performance based on the 
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306 current data. Since very few exercise-based studies have quantified GI 
307 symptoms, it may be the severity that modulates the effects on 
308 performance, rather than GI symptoms per se. This may also explain 
309 why some studies have found GI symptoms to have deleterious effects 
310 on performance with NaHCO3 supplementation (Deb et al., 2018; 
311 Cameron et al., 2010; Saunders et al., 2014) whereas others have not 
312 (Miller et al., 2016; Price & Simons, 2010). To elucidate the effects of 
313 GI disturbances on performance, future studies should look to describe 
314 the GI symptoms experienced immediately prior to exercise, as well 
315 as the athletes perceived readiness to commence.
316 Blood [HCO3–] and pH corresponded to increases typically 
317 observed with 300 mg∙kg BM NaHCO3 (Matson & Tran, 1993), 
318 however this was not observed with enteric-coated NaHCO3. Indeed, 
319 enteric-coated capsules reduced the bioavailability of bicarbonate with 
320 changes of ~ 4 mmol∙L-1 post-ingestion, which may hinder the effect 
321 on exercise performance. Bicarbonate anions are actively transported 
322 across the intestinal mucosa rather than passively and become 
323 saturated (Turnberg, 1970), which could explain why blood 
324 concentrations are reduced with enteric-coated NaHCO3. Furthermore, 
325 as enteric-coated capsules do not disintegrate until reaching the small 
326 intestine, overall GI transit time is decreased which may have 
327 contributed to reduced blood concentrations. Similar to previous work 
328 (Gough et al., 2017), changes in blood [HCO3–] and pH demonstrated 
329 a high degree of inter-individual variability following NaHCO3 
330 ingestion (Table 3).  Interestingly, changes in blood [HCO3–] were less 
331 variable with enteric-coated capsules which suggests that much of the 
332 variation derives from the degree of neutralisation in the stomach. 
333 Although blood [HCO3–] was similar between gelatine and delayed-
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334 released NaHCO3, concentrations were elevated for longer in the 
335 delayed-release form. Similarly, more participants reached 
336 concentrations that are associated with performance-enhancing effects 
337 (Carr et al., 2011b). Given that higher pre-exercise blood [HCO3–] is 
338 associated with greater performance enhancements (Carr et al., 2011b; 
339 Matson & Tran, 1993), ingestion form may alter the ergogenic 
340 potential of NaHCO3.
341 In conclusion, the ingestion of NaHCO3 in delayed-release or 
342 enteric-coated capsules attenuates GI disturbances following NaHCO3 
343 ingestion. Enteric-coated NaHCO3 is optimal for minimising GI 
344 symptoms and may be favourable for those who report GI disturbances 
345 following supplementation, even in those who have tried alternative 
346 ingestion strategies. Given the dramatic variation in the timing of peak 
347 blood [HCO3–] (60-180 min) across ingestion forms, it is 
348 recommended that athletes continue to adopt an individualised 
349 ingestion strategy. Gelatine capsules can be ingested 90 min prior to 
350 exercise for athletes without access to a blood-gas analyser, whereas 
351 delayed-release and enteric-coated NaHCO3 can be ingested 120 min 
352 before exercise commences. Given that blood buffering capacity was 
353 blunted with enteric-coated NaHCO3, future research should look to 
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Table 1. Frequency and severity of GI symptoms following NaHCO3 ingestion (n = 14). The most frequent and severe GI symptoms are highlighted 
in bold.
Overall PLA GEL DEL ENT
Symptoms % Mean ± SD % Mean ± SD % Mean ± SD % Mean ± SD % Mean ± SD
Stomach bloating 100.0 4.4 ± 1.9 0.0 0.0 ± 0.0 85.7 3.7 ± 1.8 78.6 3.6 ± 2.2 50.0 2.9 ± 1.2
Belching 92.9 3.5 ± 1.4 7.1 2.0 ± 0.0 85.7 3.4 ± 1.6 64.3 2.3 ± 1.4 57.1 2.3 ± 0.9
Bowel urgency 92.9 5.9 ± 3.0 0.0 0.0 ± 0.0 85.7 5.9 ± 3.1 71.4 3.8 ± 2.3 21.4 3.3 ± 1.5
Stomach ache 85.7 3.5 ± 2.3 14.3 1.5 ± 0.7 71.4 3.5 ± 2.6 57.1 2.2 ± 1.5 14.3 1.0 ± 0.0
Stomach cramps 78.6 4.0 ± 2.2 0.0 0.0 ± 0.0 64.3 4.4 ± 2.3 28.6 2.1 ± 0.7 7.1 3.0 ± 0.0
Flatulence 71.4 4.4 ± 2.7 0.0 0.0 ± 0.0 57.1 3.6 ± 2.9 28.6 3.0 ± 1.2 35.7 3.8 ± 2.2
Diarrhoea 64.3 7.8 ± 3.1 0.0 0.0 ± 0.0 50.0 8.2 ± 3.4 42.9 6.2 ± 2.7 7.1 5.0 ± 0.0
Nausea 57.1 3.0 ± 2.4 0.0 0.0 ± 0.0 35.7 3.6 ± 2.7 35.7 1.6 ± 1.3 7.1 4.0 ± 0.0
Vomiting 14.3 1.0 ± 1.0 0.0 0.0 ± 0.0 7.1 1.0 ± 0.0 7.1 2.0 ± 0.0 0.0 0.0 ± 0.0
Any 100.0 4.2 ± 0.8 14.3 1.8 ± 0.4 100.0 4.1 ± 1.0 85.7 3.0 ± 1.4 92.9 2.8 ± 1.5
Notes: Overall percentage includes those who reported GI symptoms after at least one NaHCO3 ingestion form.
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522 Table 2. Individual peak GI symptom reported following different NaHCO3 ingestion forms. Symptom scores are 
displayed in parentheses and are expressed as arbitrary units (AU).
Participant PLA GEL DEL ENT
1 Nil (0.0) Bowel urgency (7.0) Stomach bloating (3.0) Belching (2.0)
2 Nil (0.0) Diarrhoea (10.0) Diarrhoea (7.0) Belching (1.0)
3 Nil (0.0) Stomach bloating (4.0) Diarrhoea (5.5) Diarrhoea (5.0)
4 Nil (0.0) Bowel urgency (6.0) Flatulence (5.0) Bowel urgency (3.0)
5 Nil (0.0) Stomach cramp (6.0) Bowel urgency (2.0) Belching (3.0)
6 Stomach ache (2.0) Diarrhoea (10.0) Stomach ache (4.5) Nausea (3.0)
7 Nil (0.0) Diarrhoea (10.0) Diarrhoea (8.0) Bowel urgency (5.0)
8 Nil (0.0) Bowel urgency (4.0) Stomach cramp (1.2) Stomach bloating (3.0)
9 Nil (0.0) Diarrhoea (10.0) Stomach bloating (8.0) Flatulence (6.0)
10 Nil (0.0) Nausea (8.0) Diarrhoea (7.0) Belching (2.0)
11 Belching (1.0) Belching (5.0) Bowel urgency (2.0) Belching (1.0)
12 Nil (0.0) Stomach bloating (4.3) Nil (0.0) Nil (0.0)
13 Nil (0.0) Diarrhoea (10.0) Diarrhoea (8.5) Flatulence (5.0)
14 Nil (0.0) Stomach cramp (4.0) Stomach bloating (3.0) Nil (0.0)
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Table 3. Within-trial variation in bicarbonate kinetic variables for different NaHCO3 ingestion forms.
GEL DEL ENT
Variable Mean ± SD CV Mean ± SD CV Mean ± SD CV
Tlag (min) 21.4 ± 5.3b,c 24.9 30.0 ± 10.4a 34.6 31.4 ± 12.9a 41.1
Cmax (mmol∙L-1) 30.5 ± 1.9c 6.1 31.3 ± 1.4c 4.5 28.2 ± 0.9a,b 3.3
∆Cmax (mmol∙L-1) 6.0 ± 1.3c 22.1 6.5 ± 1.2c 17.8 4.4 ± 0.5a,b 12.0
Tmax (mmol∙L-1) 95.0 ± 31.8b 33.5 119.3 ± 24.3a 20.4 120.0 ± 35.1 29.2
AUC (mmol∙min∙L-1) 687.6 ± 307.1c 44.7 741.3 ± 237.3c 32.0 342.7 ± 190.0a,b 55.5
Notes: GEL, gelatine; DEL, delayed-release; ENT, enteric-coated; CV, coefficient of variation; Tlag, lag time; 
Cmax, peak bicarbonate concentration; ∆Cmax, change in peak bicarbonate concentration; Tmax, time to peak 
bicarbonate concentration; AUC, area under the curve. aSignificant from GEL trial (P < 0.05). bSignificant from 
DEL trial (P < 0.05). cSignificant from ENT trial (P < 0.05). CV was calculated as 100 × (SD/μ).
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525 Figure 1. Aggregated GI symptom scores (A) and mean (± SD) peak GI symptom (B) experienced following ingestion of PLA 
526 and NaHCO3 ingestion forms. Aggregated GI symptom scores include those who reported no symptoms (i.e. “0.0”). Error bars 
527 are removed for clarity. Peak GI symptom refers to the highest individual symptom reported up to 3 h post-ingestion. 
528 *Significantly greater than PLA (P < 0.05).
529 Figure 2. Mean (± standard error of the mean) blood [HCO3–] (A) and pH (B) pre- and post-ingestion. *Significant from GEL 
530 trial (P < 0.05). †Significant from DEL trial (  < 0.05).  Blood [HCO3–] is significantly greater (P < 0.05) than PLA from 20 
531 min with GEL and 40 min in the DEL and ENT trials. Blood pH is significantly greater (P < 0.05) than PLA from 40 min in 
532 the GEL and DEL trials and from 80 min with ENT.
533 Figure 3. Mean (± SD) (A) and individual (B) changes in blood [HCO3–] following ingestion of different NaHCO3 ingestion 
534 forms. *Significantly greater than PLA (P < 0.05).
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Figure 1. Aggregated GI symptom scores (A) and mean (± SD) peak GI symptom (B) experienced following 
ingestion of PLA and NaHCO3 ingestion forms. Aggregated GI symptom scores include those who reported 
no symptoms (i.e. “0.0”). Error bars are removed for clarity. Peak GI symptom refers to the highest 
individual symptom reported up to 3 h post-ingestion.*Significantly greater than PLA (P < 0.05). 
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Figure 2. Mean (± standard error of the mean) blood [HCO3–] (A) and pH (B) pre- and post-ingestion. 
*Significant from GEL trial (P < 0.05). †Significant from DEL trial (P < 0.05).  Blood [HCO3–] is significantly 
greater (P < 0.05) than PLA from 20 min with GEL and 40 min in the DEL and ENT trials. Blood pH is 
significantly greater (P < 0.05) than PLA from 40 min in the GEL and DEL trials and from 80 min with ENT. 
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Figure 3. Mean (± SD) (A) and individual (B) changes in blood [HCO3–] following ingestion of different 
NaHCO3 ingestion forms. *Significantly greater than PLA (P < 0.05). 
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